amp

Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings

NEWTON, Mass.--(BUSINESS WIRE)--Jul 9, 2007 - Pro-Pharmaceuticals,Inc. (Amex: PRW), a company "Advancing Drugs ThroughGlycoscience(R)", today updated the progress of its Phase IIclinical trial for first-line treatment of metastatic, unresectablecolorectal cancer patients who are unable to tolerate irinotecanand/or oxaliplatin, and its Phase II clinical trial for first-linetreatment of bilia...

Positive Clinical Results for DG041 Lead Product Development Highlights at deCODE R&D Event

Recent clinical studies support the development of DG041 as aneffective anti-platelet that does not increase bleeding risk REYKJAVIK, Iceland, June 25, 2007 /PRNewswire-FirstCall/ --deCODE genetics today announced progress in the development ofDG041, the company's Phase II developmental compound for theprevention of arterial thrombosis. The results of the Phase IIa andclinical pharmacolog...

Vastox Awarded £400,000 Grant to Support R&D at Carbohydrate Chemistry Facility

OXFORD, England, 20 June 2007 - VASTox plc (AIM: VOX), a leadingUK biotechnology company, announces that it has been awarded agrant of £400,000 by the Welsh Development Agency(”WDA”) under the SMARTCymru scheme. The grant,which runs for 12 months, will support the research and developmentwork undertaken at VASTox’s Aberystwyth facility and providesrecognition of...

Modigene Announces Successful Completion of Pharmacokinetic & Pharmacodynamic Pre-Clinical Experiments for Proprietary Long-Acting Human Growth Hormone, Long-acting Interferon Beta and Long-acting Erythropoietin

VIENNA, Va., June 20, 2007 /PRNewswire/ -- Modigene Inc., aNevada corporation today announced the successful completion ofpharmacokinetic and pharmacodynamic pre-clinical experiments forlong-acting human growth hormone, long-acting interferon beta andlong-acting erythropoietin. Modigene's pharmacodynamic and pharmacokinetic pre-clinicalexperiments demonstrated superb durability of...

Hemispherx Presents Evidence of Ampligen Synergies with Existing Antivirals at International Avian Influenza Conference

PARIS--(BUSINESS WIRE)--Jun 4, 2007 - Hemispherx Biopharma, Inc.(AMEX: HEB), a biopharmaceutical company engaged in the clinicaldevelopment of new drug entities for the treatment of pandemicdisease threats, announced today a new scientific report on theactivity of its experimental therapeutic Ampligen(R) in combinationwith approved anti-influenza agents against highly pathogenic avianinflue...

Acorda Therapeutics Presents Fampridine-SR Data at ACTRIMS Meeting

HAWTHORNE, N.Y.--(BUSINESS WIRE)--Jun 4, 2007 - AcordaTherapeutics, Inc.(R) (Nasdaq: ACOR) today announced that theCompany presented a "meta-analysis" or combined analysis of twoclinical trials of Fampridine-SR in multiple sclerosis during aposter session at the Americas Committee for Treatment and Researchin MS (ACTRIMS) Meeting in Washington, D.C. on Saturday, June 2,2007. The poster, "Va...

Positive Final Data from HyCAMP Phase II Trial in Metastatic Colorectal

BRISBANE, Australia, May 29, 2007 /PRNewswire/ -- Phase IIresults exceed expectations - Alchemia prepares for FDA talks onHyCAMP(TM) Australian drug development company Alchemia Limited willcommence discussions with the US Food and Drug Administration (FDA)following the successful conclusion of the Phase II clinical trialof its metastatic colorectal cancer treatment, HyCAMP(TM).</p...

Inovio Biomedical's DNA Delivery Technology Shows Safety and Enhances Gene Expression &amp; Tumor Responses in Interim Melanoma Clinical Study Results

SAN DIEGO--(BUSINESS WIRE)--May 24, 2007 - Inovio BiomedicalCorporation (AMEX:INO), focused on the development of DNA-based DNAvaccines for cancers and infectious diseases and a novelalternative to surgery to treat localized cancers, announced todaythat interim clinical trial results demonstrated that a DNA-basedimmunotherapy delivered by Inovio's electroporation technology wassafe and tole...

Catalyst Pharmaceutical Partners, Inc. Announces Top-Line Results of Its Bioequivalence Study of CPP-109 (Vigabatrin), the Company's Investigational Drug to Treat Cocaine and Methamphetamine Addiction

CORAL GABLES, Fla., May 09, 2007 /PRNewswire-FirstCall/ --Catalyst Pharmaceutical Partners, Inc. announced today positiveinitial, top-line results from a bioequivalence study demonstratingthat CPP-109 (Catalyst's Vigabatrin Tablets) is bioavailable andbioequivalent to Sabril Tablets, the version of vigabatrin marketedin Europe by Sanofi Aventis. These data potentially provide a basisfor...

Acorda Therapeutics Presents Data from its Phase 3 Study of Fampridine-SR in Multiple Sclerosis at the American Academy of Neurology Meeting

BOSTON--(BUSINESS WIRE)--May 2, 2007 - Acorda Therapeutics, Inc.(R)(Nasdaq: ACOR) today presented data from a Phase 3 clinical trialof Fampridine-SR in people with multiple sclerosis (MS) at theAmerican Academy of Neurology meeting. Andrew Goodman, M.D.,Director of the Multiple Sclerosis Center at the University ofRochester, presented top-line results on walking ability, legstrength, spasti...

New Report Illuminates Ampligen's Unique Mechanism of Action

PHILADELPHIA--(BUSINESS WIRE)--Apr 30, 2007 - Hemispherx Biopharma,Inc. (AMEX: HEB) announced today the first scientific publication(Journal of Immunology, April 2007) that explains the uniquetherapeutic properties of its proprietary experimental therapeutic,Ampligen(R) (Poly I : Poly C(12)U), a double-stranded RNA beingtested as a monotherapy for Chronic Fatigue Syndrome and as anadjuvant...

Alchemia Reports Preliminary Positive Efficacy Data From HyCAMP Phase II Trial

SYDNEY, Australia, April 26, 2007 /PRNewswire-FirstCall/ --Australian drug development company Alchemia Limited todayannounced preliminary results from its randomised Phase II clinicaltrial in patients with metastatic colorectal cancer, whereAlchemia's drug HyCAMP(TM) was compared to irinotecan which isconsidered to be a cornerstone drug for the treatment of colorectalcancer. This announ...

Cervarix, GSK Cervical Cancer Candidate Vaccine, Demonstrates 100 Percent Protection Against Precancerous Lesions Caused By Cancer-Causing Human Papillomavirus Types 16 &amp; 18 for More Than Five Years

New study results also show evidence of additional protectionagainst infection with other cancer-causing virus types LOS ANGELES, April 17, 2007 /PRNewswire-FirstCall/ -- TheGlaxoSmithKline cervical cancer candidate vaccine, CERVARIX(R),demonstrated 100 percent efficacy in preventing precancerouslesions due to cancer-causing human papillomavirus types 16 and 18for up to 5.5 years in an ex...

Arrowhead Subsidiaries Insert &amp; Calando Present Data on Cyclosert Drug Delivery System at AACR Meeting

Novel Systems May Provide Cancer Patients With Improved Potentialto Battle Their Disease PASADENA, Calif., April 16, 2007 /PRNewswire-FirstCall/ --Arrowhead Research Corporation announced today that two of itsmajority-owned subsidiaries, Insert Therapeutics Inc. and CalandoPharmaceuticals Inc., are presenting data at the 2007 AmericanAssociation for Cancer Research (AACR) Annual Meeting....

Ace Biosciences, Ace393, the World's First Commercial Vaccine for Travellers' Diarrhoea Caused by Campylobacter Successfully Completes Phase I Clinical Trials

Ace Biosciences, Ace393, the World's First Commercial Vaccinefor Travellers' Diarrhoea Caused by Campylobacter SuccessfullyCompletes Phase I Clinical Trials Trial confirms good safety profile and strong immunogenicity ODENSE, Denmark, March 28, 2007 -ACE BioSciences A/S, theinfectious diseases company is pleased to announce the successfulcompletion of Phase I clinical t...

Sarasota's Roskamp Institute Announces Positive Safety Data in Human Clinical Study for Alzheimer's Disease

And Japanese Study Suggests the Drug Improves Memory SARASOTA, Fla., March 22, 2007 /PRNewswire-FirstCall/ -- TheRoskamp Institute announced today that it has received positivepreliminary results in its major clinical study that is testing apromising new drug application for the treatment of Alzheimer'sdisease. The clinical study, which was first announced inSeptember, is the first human...

Acorda Therapeutics Presentation of Fampridine-SR Phase 3 Data Selected for Scientific Highlights Program at the American Academy of Neurology Meeting

HAWTHORNE, N.Y.--(BUSINESS WIRE)--Mar 19, 2007 - AcordaTherapeutics (Nasdaq: ACOR) today announced that Andrew Goodman,M.D., Director of the Multiple Sclerosis Center at the Universityof Rochester, will present data from Acorda's MS-F203 Phase 3clinical trial of Fampridine-SR in multiple sclerosis at theupcoming American Academy of Neurology (AAN) meeting. The platformpresentation will take...